Protalix BioTherapeutics, Inc. (PLX)
After hours:
| Previous close | 1.1600 |
| Open | 1.1700 |
| Bid | 1.1400 x 4000 |
| Ask | 1.2100 x 2900 |
| Day's range | 1.1300 - 1.1850 |
| 52-week range | 1.0900 - 3.3100 |
| Volume | |
| Avg. volume | 372,362 |
| Market cap | 83.279M |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | 12.67 |
| EPS (TTM) | 0.0900 |
| Earnings date | 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 13.00 |
PR NewswireProtalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended March 31, 2024 and provide a business and clinical update on May 10, 2024.
Insider MonkeyProtalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call Transcript
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call Transcript March 14, 2024 Protalix BioTherapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.07 EPS, expectations were $-0.03. Protalix BioTherapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, […]
- GuruFocus.com
Protalix BioTherapeutics Inc Reports Revenue Growth and Net Income Gain in FY 2023
PLX Sees Regulatory Approvals and Commercial Progress Amidst Financial Growth
